VarTrace® AML Assay


Contact us for more information.

Targeted qPCR-based assays to identify mutations down to 0.1% VAF

  • SENSITIVE: Limit of detection down to 0.1% VAF

  • QUANTITATIVE: Able to quantify mutation VAF in original sample

  • VERSATILE: Applicable to a variety of sample types

  • COMPREHENSIVE: Wide range of mutations covered

  • USER-FRIENDLY: Easy workflow

For research use only. Not for use in diagnostic procedures.

The VarTrace products enable highly sensitive detection and quantification of mutations for NSCLC, AML, melanoma patients. The kits use NuProbe’s PCR-based Blocker Displacement Amplification (BDA) technology to enable the selective amplification of low abundant sequence variants (SNV and indels) in a background of wildtype DNA. Following PCR enrichment, Sanger sequencing is applied to reveal the identity of the variants.


  • Comprehensive hematological panel: Detects 254 AML hotspot mutations in 6 genes: FLT3, DNMT3A, IDH1, IDH2, KIT, and NPM1
  • Requires 80 ng – 1.5 μg of DNA from whole blood sample
  • Rapid mutation testing: Delivers results in 8 hours, with 2.5 hours of hands-on time

Product Specifications:

Kit size EGFR, AML: 24 reactions / kit
Turnaround time Same day results
Sample type Plasma samples, tumor biopsies, paraffin-embedded sections (FFPE), and fresh frozen tumors (only blood samples for AML panels)
Sample input 10-100 ng cfDNA from blood plasma, or 10-1000 ng DNA from tissue biopsy or blood plasma


Product Offerings:

Click Here to Download List of Mutations